Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.

The addition of bevacizumab to docetaxel at the standard dose of 75 mg/m2 with or without trastuzumab was investigated in a phase II, parallel-arm study of patients with metastatic breast cancer. Docetaxel combined with bevacizumab administered every 3 weeks (in human epidermal growth factor receptor–negative [HER2−] patients, n = 52), and docetaxel plus trastuzumab plus bevacizumab (in HER2+ patients, n = 21) were feasible and safe, with high response rates and promising progression-free survival.